Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,991 shares of the biopharmaceutical company’s stock after selling 349 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Halozyme Therapeutics were worth $1,673,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC boosted its position in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics during the third quarter worth $57,000. FSC Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics in the third quarter valued at $65,000. Park Place Capital Corp lifted its stake in Halozyme Therapeutics by 828.1% in the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,209 shares during the last quarter. Finally, CWM LLC raised its position in shares of Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 668 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 0.3 %

Shares of NASDAQ:HALO opened at $55.77 on Friday. The stock has a market capitalization of $7.10 billion, a PE ratio of 18.47, a P/E/G ratio of 0.42 and a beta of 1.24. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The firm has a fifty day moving average price of $49.59 and a 200 day moving average price of $54.22.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research analyst reports. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright increased their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.